NEW YORK ( TheStreet) -- Shares of Advanced Battery Technologies (Nasdaq: ABAT) have taken a tremendous swing upward. The stock is trading at 97 cents as of 11:46 a.m. ET, 20.3% above Wednesday's closing price of 81 cents. Volume is at six million, 2.6 times the daily average of 2.3 million. Advanced Battery has a market cap of $71.3 million and is part of the industrial goods sector and industrial industry. Shares are down 79% year to date as of the close of trading on Wednesday. Advanced Battery Technologies, Inc., through its subsidiaries, engages in the design, manufacture, and marketing of rechargeable polymer lithium-ion (PLI) batteries. The company operates in two segments, Batteries and Electric Vehicles. The company has a P/E ratio of 1.6, equal to the average industrial industry P/E ratio and below the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Advanced Battery as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and a generally disappointing performance in the stock itself. You can view the full Advanced Battery Ratings Report. See our top % gaining stocks list for other stocks that are soaring today, or get investment ideas from our investment research center. Interested in other stocks that are soaring? Get free SMS text alerts sent to you when the action happens by texting SOAR to 95370 or select from multiple alert options.
HOST // Robert Powell
Retirement Planning Event
More from Markets
Dow Advances as Investors Keep an Eye on the Federal Reserve
Stocks rise Tuesday as investors turn their attention to the beginning of the two-day Federal Reserve meeting.
Jim Cramer on What Could Happen to Elon Musk's Twitter
Jim Cramer wrote about the three different scenarios that could happen to Elon Musk as Judge Nathan considers her decision.
Why Shareholders Should Vote for Bristol-Myers Celgene Deal: Jim Cramer
Jim Cramer thinks that Bristol-Myer's deal with Celgene is a positive thing, despite Starboard's resistance.